PMID- 37734442
OWN - NLM
STAT- MEDLINE
DCOM- 20231110
LR  - 20231114
IS  - 1873-1635 (Electronic)
IS  - 1350-9462 (Linking)
VI  - 97
DP  - 2023 Nov
TI  - Risk factors, clinical features and treatment of Behcet's disease uveitis.
PG  - 101216
LID - S1350-9462(23)00055-1 [pii]
LID - 10.1016/j.preteyeres.2023.101216 [doi]
AB  - Behcet's disease is a systemic vasculitis frequently associated with intraocular 
      inflammation. Recent findings identified independent clinical clusters in 
      Behcet's disease, each involving distinct combinations of affected organs. Ocular 
      Behcet's disease, mainly manifested as uveitis, is characterized as an 
      independent cluster with a low likelihood of association with other system 
      involvements, such as intestinal, cardiovascular, or central nervous system. A 
      prevailing theory suggests that the pathogenesis of the disease is 
      multifactorial, where a variety of genetic and infectious agents may interact 
      with each other to cause the disease. Among sporadic cases, the human leukocyte 
      antigen (HLA) genes, including HLA-B51, HLA-A26, HLA-B15, and HLA-B5701, have 
      been found to be a key component conferring genetic susceptibility. Outside the 
      HLA region, a set of susceptibility variants are identified, closely related to 
      interleukin (IL)-23/IL-17 pathway, tumor necrosis factor (TNF) signaling, and 
      pattern recognition receptor systems. Microbial infections, such as Streptococcus 
      sanguinis, Mycobacterium tuberculosis, and Herpes simplex virus (HSV), are linked 
      to play the triggering of disease in immunogenetically predisposed individuals. 
      Clinically, due to the notable relapsing-remitting course of ocular Behcet's 
      disease, the prevention of recurrent attack would be the primary treatment goal. 
      Combination of corticosteroids and immunomodulatory drugs, such as anti-TNF 
      agents, interferon, and conventional immunosuppressants (e.g. cyclosporine, 
      azathioprine), have been the mainstream regimen for the disease. Future research 
      may focus on comparing the effectiveness of immunomodulatory drugs and 
      identifying the most suitable subgroups for a specific drug on the basis of the 
      knowledge of the molecular heterogeneity of the disease.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Zhong, Zhenyu
AU  - Zhong Z
AD  - The First Affiliated Hospital of Chongqing Medical University, Chongqing Key 
      Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch 
      (Municipality Division) of National Clinical Research Center for Ocular Diseases, 
      Chongqing, China.
FAU - Su, Guannan
AU  - Su G
AD  - The First Affiliated Hospital of Chongqing Medical University, Chongqing Key 
      Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch 
      (Municipality Division) of National Clinical Research Center for Ocular Diseases, 
      Chongqing, China.
FAU - Yang, Peizeng
AU  - Yang P
AD  - The First Affiliated Hospital of Chongqing Medical University, Chongqing Key 
      Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch 
      (Municipality Division) of National Clinical Research Center for Ocular Diseases, 
      Chongqing, China. Electronic address: peizengycmu@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230919
PL  - England
TA  - Prog Retin Eye Res
JT  - Progress in retinal and eye research
JID - 9431859
RN  - 0 (Immunomodulating Agents)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
SB  - IM
MH  - Humans
MH  - *Behcet Syndrome/drug therapy/genetics
MH  - Immunomodulating Agents
MH  - Tumor Necrosis Factor Inhibitors/therapeutic use
MH  - *Uveitis/drug therapy/etiology
MH  - Risk Factors
OTO - NOTNLM
OT  - Behcet's disease
OT  - Clinical management
OT  - Diagnosis
OT  - Ocular disease
OT  - Risk factors
OT  - Uveitis
COIS- Declaration of competing interest The authors declare no competing financial 
      interests.
EDAT- 2023/09/22 00:42
MHDA- 2023/11/10 06:44
CRDT- 2023/09/21 19:13
PHST- 2023/06/21 00:00 [received]
PHST- 2023/09/09 00:00 [revised]
PHST- 2023/09/15 00:00 [accepted]
PHST- 2023/11/10 06:44 [medline]
PHST- 2023/09/22 00:42 [pubmed]
PHST- 2023/09/21 19:13 [entrez]
AID - S1350-9462(23)00055-1 [pii]
AID - 10.1016/j.preteyeres.2023.101216 [doi]
PST - ppublish
SO  - Prog Retin Eye Res. 2023 Nov;97:101216. doi: 10.1016/j.preteyeres.2023.101216. 
      Epub 2023 Sep 19.